Comparison between single and dual antiplatelet therapy in patients on oral anticoagulants undergoing coil embolization for unruptured intracranial aneurysms: a retrospective multicenter cohort study
Authors:
- Seung Pil BanSBSeung Pil Ban
- O-Ki KwonOKO-Ki Kwon
- Young Deok KimYKYoung Deok Kim
- Hwan Seok ShimHSHwan Seok Shim
- Seung Bin SungSSSeung Bin Sung
- Jung Cheol ParkJPJung Cheol Park
- Hyoung Soo ByounHBHyoung Soo Byoun
- Min Jai ChoMCMin Jai Cho
- Hyunjun JoHJHyunjun Jo
- Hyun ParkHPHyun Park
- Sukh Que ParkSPSukh Que Park
- Dongwook SeoDSDongwook Seo
Open Access
- 18 November 2025
- journal article
- research article
- Published by Springer Nature in Neuroradiology
- Vol. 67 (12) , 3439-3448
Abstract
Purpose: The optimal antiplatelet therapy for patients on continuous oral anticoagulants (OACs) who are undergoing coil embolization for unruptured intracranial aneurysms (UIAs) is remains unknown. This study evaluated the efficacy and safety of single- (SAPT) and dual antiplatelet therapy (DAPT) in patients taking OACs who underwent coil embolization for UIAs. Methods: This retrospective multicenter study included patients taking OACs who underwent coil embolization for UIAs at 9 hospitals between January 2016 and August 2023. The primary outcome was a thromboembolic complication within 30 days post-procedure. The secondary outcome was a composite all bleeding events according to the Thrombolysis in Myocardial Infarction bleeding criteria. Results: A total of 112 patients (mean [standard deviation] age, 67.3 [9.7]; 67 females [59.8%]) were included. Among them, 31 patients (27.7%) received SAPT, and 81 patients (72.3%) received DAPT. There was no significant difference in the thromboembolic event rate between the 2 groups (SAPT group: 2 of 31 [6.5%]; DAPT group: 3 of 81 [3.7%]; unadjusted hazard ratio [HR], 0.55 [95% CI, 0.09–3.30]; P = .52). However, the rate of all bleeding events after coil embolization in the DAPT group was significantly higher than that in the SAPT group (SAPT group: 2 of 31 [6.5%]; DAPT group: 22 of 81 [27.2%]; adjusted HR, 5.57 [95% CI, 1.30-23.83]; P = .02). Conclusions: With respect to SAPT, DAPT was not associated with a reduction in thromboembolic complications in patients taking OACs who underwent coil embolization, but it was associated with an increase in all bleeding events.Keywords
Funding Information
- Seoul National University Hospital
This publication has 23 references indexed in Scilit:
- Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionJAMA Cardiology, 2020
- Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic AttackJAMA Neurology, 2020
- Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionJAMA Cardiology, 2019
- National Trends in Ambulatory Oral Anticoagulant UseThe American Journal of Medicine, 2015
- Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary InterventionJACC, 2013
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- Combining Antiplatelet and Anticoagulant TherapiesJACC, 2009
- Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent ImplantationJACC, 2008
- Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialThe Lancet, 2006
- Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attackCochrane Database of Systematic Reviews, 2004